PharmaCorp Rx Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-1.48	-1.01	-0.47	-0.52	-0.08
Depreciation & Amortization	0.94	0.29	-	-	-
Stock-Based Compensation	0.41	0.28	-	0.39	-
Other Operating Activities	0.02	-0.14	-	-	-
Change in Accounts Receivable	-0.14	-0	-	-	-
Change in Inventory	-0.31	0.11	-	-	-
Change in Accounts Payable	2.27	0.5	-	-0.01	0.08
Change in Income Taxes	0.26	0	-	-	-
Change in Other Net Operating Assets	0.05	0.1	-0.05	0.02	-
Operating Cash Flow	2.01	0.12	-0.52	-0.12	0
Operating Cash Flow Growth	1505.50%	-	-	-	-
Capital Expenditures	-0.09	-0.01	-	-	-
Cash Acquisitions	-12.61	-16.86	-	-	-
Other Investing Activities	-1.02	-	-	-	-
Investing Cash Flow	-13.72	-16.86	-	-	-
Long-Term Debt Issued	3.16	-	-	-	-
Long-Term Debt Repaid	-0.32	-0.11	-	-	-
Net Debt Issued (Repaid)	2.84	-0.11	-	-	-
Issuance of Common Stock	21.44	27.49	0.03	2	3
Other Financing Activities	0.43	-	-	-0.13	-0.06
Financing Cash Flow	24.71	27.38	0.03	1.87	2.94
Net Cash Flow	13	10.64	-0.49	1.75	2.94
Free Cash Flow	1.92	0.12	-0.52	-0.12	0
Free Cash Flow Growth	1525.00%	-	-	-	-
Free Cash Flow Margin	9.18%	2.04%	-	-	-
Free Cash Flow Per Share	0.01	0.00	-0.03	-0.01	-
Levered Free Cash Flow	1.85	-0.54	-0.41	0.04	-
Unlevered Free Cash Flow	1.89	-0.54	-0.41	0.04	-
Change in Working Capital	2.13	0.71	-0.05	0.01	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.